Date de publication

14 janvier 2020

Auteur(s)

Krakower,D., Daskalakis, D., et autres.

Description

In early 2019, the U.S. government launched the Ending the HIV Epidemic initiative, which aims to reduce HIV incidence by 90% before 2030. Daily preexposure prophylaxis (PrEP) with a single pill containing tenofovir disoproxil fumarate with emtricitabine (TDF–FTC) virtually eliminates sexual HIV transmission, and scale-up of PrEP is a critical component of the federal initiative. Before TDF–FTC was used for PrEP, it was a cornerstone of HIV treatment, but it has been largely replaced by tenofovir alafenamide with emtricitabine (TAF–FTC), a newer regimen that was believed to be equally effective but safer. As we embark on a national effort to scale up PrEP, should we also abandon TDF–FTC in favor of TAF–FTC for HIV prevention?